Calcium supplementation in chronic kidney disease

Expert Opinion on Drug Safety

Volumn 13, Issue 9, 2014, Pages 1175-1185

  Taksande, Sushant Ramdas ^a,b   Worcester, Elaine M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Nephrologyx Nephrology   (United States)

Author keywords

Calcium acetate; Calcium binders; Calcium carbonate; Calcium supplements; Cardiovascular disease; Chronic kidney disease; End stage renal disease; Lanthanum salts; Milk alkali syndrome; Renal osteodystrophy; Sevelamer; Vascular calcification

Indexed keywords

CALCIUM; PHOSPHATE BINDING AGENT; CALCIUM DERIVATIVE;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE METABOLISM; CALCIUM ABSORPTION; CALCIUM BALANCE; CALCIUM INTAKE; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIETARY INTAKE; DRUG DOSE REGIMEN; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MILK ALKALI SYNDROME; MINERAL SUPPLEMENTATION; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHYSIOLOGY; POPULATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; REVIEW; CALCINOSIS; CHEMICALLY INDUCED; DIET SUPPLEMENTATION; DOSE RESPONSE; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

CALCINOSIS; CALCIUM COMPOUNDS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERPHOSPHATEMIA; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84906263276     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.937421     Document Type: Review

References (81)

1. Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. Med Clin North Am 2005;89(3):631-47
2. Haden ST, Brown EM, Hurwitz S, et al. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf) 2000;52(3):329-38
3. Tejwani V, Qian Q. Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients 2013;5(6):1913-36
4. Khanal RC, Nemere I. Regulation of intestinal calcium transport. Annu Rev Nutr 2008;28:179-96
5. Bronner F. Mechanisms of intestinal calcium absorption. J Cell Biochem 2003;88(2):387-93
6. Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol 2010;5(Suppl 1):S23-30
7. Topala CN, Bindels RJ, Hoenderop JG. Regulation of the epithelial calcium channel TRPV5 by extracellular factors. Curr Opin Nephrol Hypertens 2007;16(4):319-24
8. Weaver CM, Martin BR, Plawecki KL, et al. Differences in calcium metabolism between adolescent and adult females. Am J Clin Nutr 1995;61(3):577-81
9. Gallagher JC, Riggs BL, Eisman J, et al. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest 1979;64(3):729-36
10. Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002;48(2):62-71
11. Nordin BE. Calcium balance and calcium requirement in spinal osteoporosis. Am J Clin Nutr 1962;10:384-90
12. Heshmati HM, Khosla S, Burritt MF, et al. A defect in renal calcium conservation may contribute to the pathogenesis of postmenopausal osteoporosis. J Clin Endocrinol Metab 1998;83(6):1916-20
13. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323(13):878-83
14. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328(7):460-4
15. Reid IR, Ames R, Mason B, et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008;168(20):2276-82
16. Reid IR, Mason B, Horne A, et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006;119(9):777-85
17. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006;166(8):869-75
18. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354(7):669-83
19. Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(12):827-38
20. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370(9588):657-66
21. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336(7638):262-6
22. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691
23. Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040
24. Xiao Q, Murphy RA, Houston DK, et al. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med 2013;173(8):639-46
25. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26(1):35-41
26. Moyer VA; Force* USPST. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158(9):691-6
27. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-8
28. Genuth SM, Vertes V, Leonards JR. Oral calcium absorption in patients with renal failure treated by chronic hemodialysis. Metabolism 1969;18(2):124-31
29. Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P. Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease. Am J Nephrol 2012;35(5):434-41
30. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43(5):877-90
31. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
32. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333(3):166-74
33. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012;81(11):1116-22
34. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83(5):959-66
35. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol 2010;5(Suppl 1):S12-22
36. Gotch F, Levin NW, Kotanko P. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif 2010;29(2):163-76
37. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305
38. Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006;21(3):707-14
39. Temmar M, Liabeuf S, Renard C, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010;28(1):163-9
40. McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and endstage renal disease: a systematic review. J Nephrol 2004;17(2):205-15
41. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-83
42. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004;95(6):560-7
43. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19(2):213-16
44. Moe SM, Chen NX, Newman CL, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 2014;29(4):902-10
45. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68(4):1815-24
46. Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011;57(3):422-31
47. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72(10):1255-61
48. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
49. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315(3):157-61
50. Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991;17(5):544-50
51. Suki WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr 2008;18(1):91-8
52. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54(4):619-37
53. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24(10):3168-74
54. Di Iorio B, Bellasi A, Russo D, Investigators IS. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7(3):487-93
55. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006;69(11):1945-53
56. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005;63(4):284-9
57. Malluche HH, Porter DS, Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol 2013;9(11):671-80
58. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58(1):396-9
59. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36(6):1115-21
60. Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 2014;85(1):166-73
61. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006;17(11):3223-32
62. Gerakis A, Hadjidakis D, Kokkinakis E, et al. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000;13(6):437-43
63. Araujo SM, Ambrosoni P, Lobao RR, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int 2003;(Suppl 85):S54-6
64. Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012;23(4):1191-8
65. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15(7):1943-51
66. Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19(2):405-12
67. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20(8):1653-61
68. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clin Pract 2008;110(4):c273-83
69. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;(Suppl 85):S73-8
70. Medarov BI. Milk-alkali syndrome. Mayo Clin Proc 2009;84(3):261-7
71. Felsenfeld AJ, Levine BS. Milk alkali syndrome and the dynamics of calcium homeostasis. Clin J Am Soc Nephrol 2006;1(4):641-54
72. Beall DP, Henslee HB, Webb HR, Scofield RH. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006;331(5):233-42
73. Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005;63(5):566-76
74. Insititute of Medicine. Dietary reference intakes for calcium and vitamin D. National Academic Press, Washington, DC; 2011
75. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266
76. Bostick RM, Kushi LH, Wu Y, et al. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999;149(2):151-61
77. Iso H, Stampfer MJ, Manson JE, et al. Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. Stroke 1999;30(9):1772-9
78. Evenepoel P, Wolf M. A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney Int 2013;83(5):789-91
79. Bernard L, Mendelssohn D, Dunn E, et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ 2013;16(1):1-9
80. Thompson M, Bartko-Winters S, Bernard L, et al. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ 2013;16(6):744-55
81. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;(Suppl 113):S1-130